GE Healthcare Appoints Emmanuel Ligner as General Manager
News Apr 11, 2014
GE Healthcare Life Sciences has announced the appointment of Emmanuel Ligner as General Manager, Global Commercial for BioProcess.
In this newly-created role Emmanuel will oversee all worldwide commercial activities of GE Healthcare Life Sciences' rapidly growing BioProcess business, which provides innovative “start-to-finish” technologies and services for the biopharmaceutical and vaccine manufacturing industry. Emmanuel reports to Nigel Darby, Vice President, BioProcess.
In March 2014 GE Healthcare Life Sciences expanded its offerings for the biopharmaceutical manufacturing industry through the acquisition of HyClone™ cell culture sera and media.
This investment and other innovations such as KUBio™ modular facility for the production of monoclonal antibodies are core to GE Healthcare’s strategy of helping the biopharmaceutical industry improve product yields and reduce time-to-market.
Before moving into this global role, Emmanuel was General Manager Commercial EMEA in January 2012, joining GE Healthcare in 2008 when the company acquired Whatman plc, a global supplier of filters and membranes for laboratory research, life sciences and medical diagnostic applications. Prior to Whatman, Emmanuel held a number of appointments in Japan with Abbott Diagnostics.
Horizon Enters into Partnership with Pirbright Institute to Improve Vaccine YieldsNews
Extends Horizon’s biomanufacturing capabilities into vaccine manufacture. Research supported by a grant from the Canadian International Development Research Centre, funded by the Bill and Melinda Gates foundation.READ MORE
Lonza Opens World’s Largest Dedicated Cell-and-Gene-Therapy Manufacturing Facility in TexasNews
First-of-its-kind, state-of-the-art manufacturing facility with capacity to produce treatment for thousands of patients suffering from rare genetic disorders or life-threatening diseases.READ MORE
IONTAS and IGEM Therapeutics Collaborate to Identify Novel IgE AntibodiesNews
The project will add to IGEM’s pipeline of drugs and expand upon IGEM-F, an IgE targeting ovarian and other cancers, currently in a Phase 1/2a study.READ MORE
Comments | 0 ADD COMMENT
International Conference on Analytical and Bio Analytical Techniques
Oct 31 - Nov 01, 2018
16th Annual Conference on Laboratory Medicine and Pathology
Sep 17 - Sep 18, 2018